Connecting the dots...Provectus Biopharmaceuticals: $PVCT's PV-10 and $VICL's Allovectin-7

May 16, 2013

$PVCT's PV-10 and $VICL's Allovectin-7

I know this comparison is spurious because apples are not being compared to apples. Nevertheless, it's interesting [at least to me] to consider. Both companies, Provectus and Vical, released information at conferences regarding combination therapies.

In November 2012 Vical released animal data at the 9th International Congress of the Society for Melanoma Research documenting the benefits of combining Allovectin-7 with anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies. The poster is here.

In April 2013 Provectus released data at the American Association for Cancer Research (AACR) Annual Meeting documenting the benefits of combining PV-10 with an anti-CTLA-4 antibody. The poster is here.

Vical's methodology was:

Provectus' low dose (of the anti-CTLA4 antibody) methodology was:

Allovectin's survival graph:

PV-10' low dose (of 9H10) survival graph:

The PV-10 legend is to the left.

No comments:

Post a Comment

Disclaimer

This blog is neither intended to be nor is investment advice. The author of this blog (the "Author") is not a registered investment advisor. Under no circumstances should any content from this blog be used or interpreted as a recommendation of a trade or investment in Provectus Biopharmaceuticals, Inc. Trading and investing can be hazardous to your wealth, health or both. Any investment decision must, in all cases and without exception, be made by the reader or by his or her registered investment advisor. This blog is only and strictly for educational and informational purposes. The Author may have a position in Provectus Biopharmaceuticals, Inc. at any given time that is not disclosed at the time of publication. All opinions expressed by the Author are subject to change without notice. You, the reader, should always obtain current information and perform the appropriate due diligence before making any investment or trading decision. All efforts are made to ensure the information contained in the blog and/or a blog post is factual and accurate; however, the Author does not guarantee its accuracy under any circumstances.

♢ Note: Provectus' board of directors appointed the Author as a special adviser to the board in February 2017. See the blog's Disclosures page.

♢♢ Note: The Author and others entered into a securities transaction with Provectus. See the blog's Disclosures page.